Small Cap Companies Exceed Expectations in Volatile Markets, with Penny Plays Showing Investors Huge Potential

DELRAY BEACH, FL / ACCESSWIRE / October 22, 2015 / Across the board, savvy investors have shown an interest in small caps low-priced shares in exchange for a possible large potential return. In an uncertain market across hundreds of varied sectors, a handful of small cap stocks continue to outshine the rest by staying competitive with either business specialization or diverse business operations.

One such comprehensive contender is CD International Enterprises, Inc. (CDII), which recently broke away from more traditional cash flow industries such as legacy manufacturing to focus on generating new revenue streams from business management and trading deals. In transitioning toward a greater emphasis on consultation-based projects in the company’s well-established global network, CDII is currently connected with trading deals pertaining to copper concentrate and steel scrap, which could generate tens of millions of dollars in revenue and provide the company a dramatically improved market share within the next 24 months.

The company’s history in the mineral and mining sectors place CD International in an advantageous position to undertake lucrative transactions on a global scale. As a direct result of two major deals with one of the world’s largest port owners, APM Terminal, CDII stands to earn a significant consulting fee for facilitating major port construction projects across South America. With business connections formerly forged through legacy manufacturing in China, the company has further begun to establish an industry presence in Africa, thereby expanding its consulting and development client base.

CD International has also desired to diversify their business operations while maintaining a presence in the Chinese market and beyond through its recent entering into an agreement of acquisition, HK International Finance & Investment Group Limited. The procurement of HK International, which is a Hong Kong-based holding company, adds health endowment and construction design to CDII’s enterprisal repertoire, allowing the company to touch upon market revenue previously not within its reach.

Another small cap company to look into in the bioscience market is PharmaCyte Biotech Inc. (PMCB), with a current market cap of 87.95 million. The use of their flagship technology Cell-in-a-Box, which utilizes encapsulated live cells, in conjunction with low doses of infosfamide have outperformed other pancreatic cancer chemotherapy drugs during early stages of clinical trials, providing an unmet critical niche for patients whose tumors have not shown either progress or reduction to other advanced cancer treatments.

Recent news in the small cap pharmaceutical sector, Elite Pharmaceuticals, Inc. (ELTP) soared yesterday on high volume of over six million shares traded. Elite Pharmaceuticals, Inc. announced positive top-line results from the Phase 3 pivotal trial of its lead opioid abuse-deterrent candidate, ELI-200, for the treatment of moderate to severe pain. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite owns generic and OTC products which have been licensed to TAGI Pharma, Epic Pharma and Valeant Pharmaceuticals International. Elite currently has eight commercial products being sold, additional approved products pending manufacturing site transfer and a product under review pending approval by the FDA.

Global Equity International, Inc. (GEQU) entered into two major international agreements with high-profile business ventures within the last month through its fully-owned subsidiary, Global Equity Partners Plc. The company will be providing specialized consulting services to International FIM SRL, an Italian automotive parts manufacturer based in Milan, and the Middle East Prospect Exhibition, which seeks to enjoin investors with energy and petroleum companies in the region.

Broadly speaking, bullish business sectors boast a proud variety of small cap stocks for investors interested in diversifying their portfolios at a low cost. Versatile companies, particularly those actively engaged in varied business endeavors such as CD International, provide an exciting option for high-growth potential in a rapidly growing market.

Seraphim Strategies is a third party publisher. Not a registered broker/dealer/analyst/adviser, holds no investment licenses and may not sell, offer to sell or offer to buy any security. Market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is not to be interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. For full disclaimer please read http://tomorrowsbluechips.com/disclaimer/ This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

“Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

SOURCE: Seraphim Strategies LLC

ReleaseID: 432874